CATALYST PHARMACEUTICAL PARTNERS, INC. Form 8-K April 02, 2013

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 2, 2013

CATALYST PHARMACEUTICAL PARTNERS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware (State or other jurisdiction

001-33057 (Commission 76-0837053 (I.R.S. Employer

of incorporation) File Number) Identification No.)

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

355 Alhambra Circle

Suite 1500

Coral Gables, Florida 33134
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (305) 529-2522

Not Applicable

Former Name or Former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

Item 8.01 Other Events

On April 2, 2013, the Company issued a press release announcing its results of operations for the fourth quarter and the year ended December 31, 2012. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release issued by the Company on April 2, 2013.

Edgar Filing: CATALYST PHARMACEUTICAL PARTNERS, INC. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Catalyst Pharmaceutical Partners, Inc.

By: /s/ Alicia Grande Alicia Grande Vice President, Treasurer and CFO

Dated: April 2, 2013